BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3935372)

  • 1. Cholesterol and HDL-cholesterol values in women during use of subdermal implants releasing levonorgestrel.
    Holma P; Robertson DN
    Contraception; 1985 Aug; 32(2):163-71. PubMed ID: 3935372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First year clinical experience with six levonorgestrel rods as subdermal contraception.
    Faundes A; Brache de Mejias V; Leon P; Robertson D; Alvarez F
    Contraception; 1979 Aug; 20(2):167-75. PubMed ID: 487818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levonorgestrel plasma levels during continuous administration with different models of subdermal implants.
    Alvarez F; Brache V; Faundes A; Johansson ED; Odlind V; Nash H
    Contraception; 1983 Feb; 27(2):123-30. PubMed ID: 6406138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of Implanon on lipid metabolism in comparison with Norplant.
    Suherman SK; Affandi B; Korver T
    Contraception; 1999 Nov; 60(5):281-7. PubMed ID: 10717780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of levonorgestrel and free levonorgestrel index in women using NORPLANT implants or two covered rods (NORPLANT-2).
    Olsson SE; Odlind V; Johansson ED; Nordström ML
    Contraception; 1987 Mar; 35(3):215-28. PubMed ID: 3111784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.
    Haukkamaa M
    Contraception; 1986 Jun; 33(6):559-65. PubMed ID: 3095023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contraception with subdermal implants releasing levonorgestrel. A clinical and pharmacological study.
    Olsson SE
    Acta Obstet Gynecol Scand Suppl; 1987; 142():1-45. PubMed ID: 3116821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study on the effects of Norplant implantable contraceptive on lipid, lipoprotein, and apolipoprotein metabolism in Singaporean women.
    Singh K; Ratnam SS
    Contraception; 1997 Aug; 56(2):77-83. PubMed ID: 9315415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen levels in women using Norplant implants.
    Olsson SE; Odlind V; Johansson E
    Contraception; 1986 Aug; 34(2):157-67. PubMed ID: 2946553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norplant contraceptive implants: rods versus capsules.
    Pasquale SA; Brandeis V; Cruz RI; Kelly S; Sweeney M
    Contraception; 1987 Sep; 36(3):305-16. PubMed ID: 3119287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum lipid profile in women using levonorgestrel contraceptive implant, Norplant-2.
    Dash DS; Das S; Nanda U; Tripathy BB; Samal KC
    Contraception; 1988 Apr; 37(4):371-82. PubMed ID: 3133159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new delivery system for contraceptive steroids.
    Segal S
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1090-2. PubMed ID: 3118719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levonorgestrel and progesterone levels in women treated with silastic covered rods containing levonorgestrel.
    Croxatto HB; Díaz S; Brandeis A; Pavez M; Johansson ED
    Contraception; 1985 Jun; 31(6):643-54. PubMed ID: 3930143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
    Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
    Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of subdermal levonorgestrel contraceptive implants, Norplant, on serum lipids.
    Shaaban MM; Elwan SI; Abdalla SA; Darwish HA
    Contraception; 1984 Nov; 30(5):413-9. PubMed ID: 6440737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term reversible contraception with levonorgestrel-releasing Silastic rods.
    Roy S; Mishell DR; Robertson DN; Krauss RM; Lacarra M; Duda MJ
    Am J Obstet Gynecol; 1984 Apr; 148(7):1006-13. PubMed ID: 6424474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Norplant contraceptive subdermal implants on serum lipids and lipoproteins.
    Otubu JA; Towobola OA; Aisien AO; Ogunkeye OO
    Contraception; 1993 Feb; 47(2):149-59. PubMed ID: 8449015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subdermal progestin implant contraception.
    Darney PD
    Curr Opin Obstet Gynecol; 1991 Aug; 3(4):470-6. PubMed ID: 1908716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
    Sivin I; Stern J; Diaz S; Pavéz M; Alvarez F; Brache V; Mishell DR; Lacarra M; McCarthy T; Holma P
    Am J Obstet Gynecol; 1992 Apr; 166(4):1208-13. PubMed ID: 1566771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.